CYRX
Neutral signalScored 2026-08-13 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Research, not advice.
À propos
Cryoport, Inc.
- Nom
- Cryoport, Inc.
- Secteur
- Industrials
- Industrie
- Integrated Freight & Logistics
- Bourse
- NASDAQ
- Capitalisation
- $910.7M
- Employés
- 688
- PDG
- Jerrell W. Shelton
- Site web
- https://www.cryoportinc.com
- Marché
- AZTACJMB
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
VENTE TOTALE: 28 800 titres (~429 384,96 $ US)
- Insiders
- SHELTON JERRELL
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$429,385
Avg sell (VWAP, 90d window) $14.91 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$429,385 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-11 | SHELTON JERRELL | Sell · S · 10b5-1 | 28,800 | $14.91 | $429,385 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2023-09-15 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2022-02-28 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-31 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2022-01-13 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2021-09-21 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-11-24 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-17 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-11-13 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-11-02 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-05-07 | Donald Sternoff Beyer | Sale (Full) | $1,001 - $15,000 |
| 2020-02-18 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2020-02-06 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-01-14 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-01-13 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
| 2019-12-23 | Donald Sternoff Beyer | Purchase | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-08-13 Drivers: fundamentals. Insiders: neutral. Moteurs : fondamentaux. Initiés : neutre.
Despite a moderate earnings catalyst (Q2 beat, 8% YoY revenue growth, Zacks upgrade), CYRX's severely weak financial foundation — persistent negative operating cash flows, negative interest coverage, and high cash burn…
The first sentence of the analysis written for CYRX on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Unavailable or mixed. – Insider: neutral. All sales (≈ $429K) were pre-planned Rule 10b5-1 trades, excluded from the score. No open-market buys or discretionary sales. – Initiés : neutre. Toutes les ventes (≈ $429K) sont sous plan 10b5-1 préétabli, exclues du score. Aucun achat ni vente discrétionnaire.
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Unavailable or mixed. Current ratio 2.17 · operating margin -21% — readings disagree
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 47.1% | 42.6% | 43.8% | 43.4% | 43.4% | |
| Ebit Margin | -16.9% | -40.2% | -12.2% | -120.9% | -120.9% | |
| Ebitda Margin | -1.2% | -28.4% | -2.6% | -111.8% | -111.8% | |
| Operating Profit Margin | -20.9% | -49.4% | -13.4% | -8.0% | -8.0% | |
| Pretax Profit Margin | -18.3% | -42.6% | -14.8% | -123.0% | -123.0% | |
| Continuous Operations Profit Margin | -19.3% | -42.7% | -15.7% | -123.8% | -123.8% | |
| Net Profit Margin | 44.4% | -42.7% | -15.7% | -123.8% | -123.8% | |
| Bottom Line Profit Margin | 39.9% | -46.1% | -19.1% | -127.5% | -127.5% | |
| Current Ratio | 2.174 | 5.291 | 11.732 | 14.790 | 16.263 | |
| Quick Ratio | 2.068 | 4.942 | 11.158 | 14.112 | 15.876 | |
| Solvency Ratio | 0.404 | -0.239 | -0.031 | -0.529 | -0.542 | |
| Cash Ratio | 1.144 | 0.701 | 1.016 | 0.896 | 3.262 | |
| Price To Earnings Ratio | 6.857 | -3.520 | -16.656 | -2.807 | -9.574 | |
| Price To Earnings Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Forward Price To Earnings Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Price To Earnings Diluted Ratio | 6.857 | -3.520 | -16.656 | -2.807 | -9.574 | |
| Price To Earnings Diluted Growth Ratio | -0.042 | -0.026 | 0.196 | 0.000 | -0.044 | |
| Price To Book Ratio | 0.956 | 0.943 | 1.552 | 1.434 | 4.234 | |
| Price To Sales Ratio | 2.728 | 1.626 | 3.198 | 3.580 | 12.208 | |
| Price To Free Cash Flow Ratio | -17.115 | -11.293 | -16.620 | -30.591 | -160.982 | |
| Price To Operating Cash Flow Ratio | -56.024 | -23.230 | -1,002.395 | -430.494 | 334.425 | |
| Debt To Assets Ratio | 0.302 | 0.356 | 0.434 | 0.420 | 0.384 | |
| Debt To Equity Ratio | 0.459 | 0.624 | 0.851 | 0.784 | 0.665 | |
| Debt To Capital Ratio | 0.315 | 0.384 | 0.460 | 0.440 | 0.400 | |
| Long Term Debt To Capital Ratio | 0.002 | 0.315 | 0.437 | 0.423 | 0.387 | |
| Financial Leverage Ratio | 1.522 | 1.750 | 1.958 | 1.869 | 1.734 | |
| Working Capital Turnover Ratio | 0.660 | 0.609 | 0.451 | 0.367 | 0.584 | |
| Operating Cash Flow Ratio | -0.039 | -0.253 | -0.017 | -0.045 | 0.191 | |
| Operating Cash Flow Sales Ratio | -0.049 | -0.070 | -0.003 | -0.008 | 0.037 | |
| Free Cash Flow Operating Cash Flow Ratio | 3.273 | 2.057 | 60.313 | 14.072 | -2.077 | |
| Debt Service Coverage Ratio | -0.021 | -3.339 | -1.339 | -52.767 | -53.443 | |
| Interest Coverage Ratio | -15.589 | -20.926 | -5.194 | -3.802 | -3.802 | |
| Short Term Operating Cash Flow Coverage Ratio | -0.046 | -1.130 | -5.081 | -30.850 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.037 | -0.065 | -0.002 | -0.004 | 0.019 | |
| Capital Expenditure Coverage Ratio | -0.440 | -0.946 | -0.017 | -0.076 | 0.325 | |
| Dividend Paid And Capex Coverage Ratio | -0.440 | -0.946 | -0.017 | -0.076 | 0.325 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -219.796 | -8.810 | -182.394 | -4.806 | -12.075 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 47.1% | ▲4.6% | ▲3.1% |
| Ebit Margin | -16.9% | ▲23.3% | ▲45.3% |
| Ebitda Margin | -1.2% | ▲27.3% | ▲50.0% |
| Operating Profit Margin | -20.9% | ▲28.5% | ▼-0.9% |
| Pretax Profit Margin | -18.3% | ▲24.3% | ▲46.1% |
| Continuous Operations Profit Margin | -19.3% | ▲23.4% | ▲45.8% |
| Net Profit Margin | 44.4% | ▲87.1% | ▲96.8% |
| Bottom Line Profit Margin | 39.9% | ▲86.0% | ▲96.0% |
| Current Ratio | 2.174 | ▼-3.116 | ▼-7.876 |
| Quick Ratio | 2.068 | ▼-2.874 | ▼-7.563 |
| Solvency Ratio | 0.404 | ▲0.643 | ▲0.591 |
| Cash Ratio | 1.144 | ▲0.442 | ▼-0.260 |
| Price To Earnings Ratio | 6.857 | ▲10.377 | ▲11.997 |
| Price To Earnings Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Forward Price To Earnings Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Price To Earnings Diluted Ratio | 6.857 | ▲10.377 | ▲11.997 |
| Price To Earnings Diluted Growth Ratio | -0.042 | ▼-0.016 | ▼-0.059 |
| Price To Book Ratio | 0.956 | ▲0.013 | ▼-0.868 |
| Price To Sales Ratio | 2.728 | ▲1.103 | ▼-1.939 |
| Price To Free Cash Flow Ratio | -17.116 | ▼-5.823 | ▲30.205 |
| Price To Operating Cash Flow Ratio | -56.024 | ▼-32.795 | ▲179.519 |
| Debt To Assets Ratio | 0.302 | ▼-0.055 | ▼-0.077 |
| Debt To Equity Ratio | 0.459 | ▼-0.165 | ▼-0.218 |
| Debt To Capital Ratio | 0.315 | ▼-0.070 | ▼-0.085 |
| Long Term Debt To Capital Ratio | 0.002 | ▼-0.313 | ▼-0.311 |
| Financial Leverage Ratio | 1.522 | ▼-0.229 | ▼-0.245 |
| Working Capital Turnover Ratio | 0.660 | ▲0.051 | ▲0.126 |
| Operating Cash Flow Ratio | -0.039 | ▲0.214 | ▼-0.006 |
| Operating Cash Flow Sales Ratio | -0.049 | ▲0.021 | ▼-0.030 |
| Free Cash Flow Operating Cash Flow Ratio | 3.273 | ▲1.216 | ▼-12.254 |
| Debt Service Coverage Ratio | -0.021 | ▲3.318 | ▲22.161 |
| Interest Coverage Ratio | -15.589 | ▲5.337 | ▼-5.726 |
| Short Term Operating Cash Flow Coverage Ratio | -0.046 | ▲1.084 | ▲7.375 |
| Operating Cash Flow Coverage Ratio | -0.037 | ▲0.028 | ▼-0.019 |
| Capital Expenditure Coverage Ratio | -0.440 | ▲0.506 | ▼-0.209 |
| Dividend Paid And Capex Coverage Ratio | -0.440 | ▲0.506 | ▼-0.209 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -219.796 | ▼-210.986 | ▼-134.220 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $480.7M | $379.2M | $758.8M | $796.8M | $2.72B | |
| Enterprise value | $460.9M | $584.6M | $1.13B | $1.20B | $3.01B | |
| EV / Sales | 2.62x | 2.51x | 4.76x | 5.37x | 13.50x | |
| EV / Op. cash flow | -53.72x | -35.81x | -1490.71x | -646.22x | 369.86x | |
| EV / Free cash flow | -16.41x | -17.41x | -24.72x | -45.92x | -178.04x | |
| EV / EBITDA | -219.80x | -8.81x | -182.39x | -4.81x | -12.07x | |
| Net debt / EBITDA | 9.43x | -3.10x | -59.75x | -1.60x | -1.16x | |
| Current ratio | 2.17x | 5.29x | 11.73x | 14.79x | 16.26x | |
| Income quality | -0.11x | 0.14x | 0.01x | 0.05x | -0.03x | |
| Graham number | $19 | — | — | — | — | |
| Graham net-net | $4 | $0 | $1 | $2 | $4 | |
| Tax burden | -243.4% | 100.2% | 106.4% | 100.6% | 100.6% | |
| Interest burden | 107.9% | 105.9% | 121.2% | 101.7% | 101.7% | |
| Working capital | $257.2M | $277.0M | $489.5M | $563.3M | $650.9M | |
| Invested capital | $542.8M | $635.2M | $909.8M | $995.9M | $1.07B | |
| Return on assets | 10.2% | -14.2% | -3.9% | -26.5% | -24.8% | |
| Operating ROA | -5.0% | -13.9% | -3.2% | -1.7% | -2.1% | |
| Return on tangible assets | 13.0% | -20.7% | -5.7% | -39.6% | -36.0% | |
| Return on equity | 15.6% | -24.8% | -7.6% | -49.6% | -42.9% | |
| Return on invested capital | -5.0% | -17.5% | -3.5% | -1.8% | -1.7% | |
| Return on capital employed | -6.7% | -18.0% | -3.5% | -1.8% | -1.7% | |
| Earnings yield | 16.3% | -26.3% | -4.9% | -34.6% | -10.1% | |
| Free cash flow yield | -5.8% | -8.9% | -6.0% | -3.3% | -0.6% | |
| Capex / Op. cash flow | -227.3% | -105.7% | -5931.3% | -1307.2% | 307.7% | |
| Capex / Depreciation | 70.4% | 56.1% | 163.3% | 106.3% | 123.5% | |
| Capex / Sales | 11.1% | 7.4% | 18.9% | 10.9% | 11.2% | |
| SG&A / Sales | 58.4% | 63.0% | 50.6% | 43.8% | 43.8% | |
| R&D / Sales | 9.7% | 7.7% | 6.6% | 7.6% | 7.6% | |
| Stock comp / Sales | 6.3% | 8.4% | 9.6% | 9.0% | 6.9% | |
| Intangibles / Total assets | 21.0% | 31.6% | 31.6% | 32.9% | 31.3% | |
| Days sales outstanding | 69d | 72d | 65d | 72d | 65d | |
| Days payables outstanding | 60d | 71d | 71d | 78d | 83d | |
| Operating cycle | 160d | 133d | 136d | 152d | 112d | |
| Cash conversion cycle | 100d | 62d | 65d | 74d | 30d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-11 CryoPort (CYRX) Upgraded to Buy: Here''s Why CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- 2026-08-07 Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript Cryoport, Inc. (CYRX) Q2 2026 Earnings Call Transcript
- 2026-08-06 CryoPort Q2 Earnings Call Highlights CryoPort NASDAQ: CYRX reported second-quarter 2026 revenue of $49 million and said it reached positive adjusted EBITDA from continuing operations, while reaffirming its full-year revenue outlook of $192 million to $196 million.
- 2026-08-06 CryoPort, Inc. (CYRX) Reports Q2 Loss, Beats Revenue Estimates CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.2 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.29 per share a year ago.
- 2026-08-06 Cryoport Reports Second Quarter 2026 Financial Results Second quarter revenue grew 8% year-over-year to $49.0 million Life Sciences Services revenue increased 15% year-over-year BioStorage/BioServices revenue grew 25% year-over-year Supporting 779 global clinical trials and 22 commercially approved cell and gene therapies (CGT) as of June 30, 2026 NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.
- 2026-07-23 Cryoport to Report Second Quarter 2026 Financial Results on August 6, 2026 NASHVILLE, Tenn., July 23, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the second quarter ended June 30, 2026 on Thursday, August 6, 2026 after U.S. markets close.
- 2026-06-25 Cryoport''s IntegriCell® Cryopreservation Services Selected by Verismo Therapeutics to Support Clinical KIR-CAR T Cell Therapy Programs IntegriCell Provides Process Development, Technology Transfer, and Clinical Cryopreservation Services Supporting Verismo''s Novel Multi-chain KIR-CAR Programs for Lead Candidates SynKIR™-110 and SynKIR™-310 NASHVILLE, Tenn., June 25, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that Cryoport Systems'' IntegriCell® cryopreservation services have been selected by Verismo Therapeutics, a clinical-stage CAR T cell therapy company pioneering a novel multi-chain KIR-CAR platform technology for the treatment of solid tumors (SynKIR™-110) and B cell associated disorders and malignancies (SynKIR™-310).